Market Overview

Chardan Analyst Suggests An AveXis-Ionis Pair Trade

Share:
Chardan Analyst Suggests An AveXis-Ionis Pair Trade
Related
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Related
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed (Seeking Alpha)

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) had announced on December 23, 2016, the U.S. FDA approval for Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) types 1 to 3.

Safety Concerns

However, with regard to the safety profile of the drug, Chardan Capital’s Gbola Amusa pointed out that 23 percent of the SMA type 1 patients treated with Spinraza died, as compared to 43 percent of the untreated patients.

On the other hand, the Phase 1 trials by AveXis Inc (NASDAQ: AVXS) for its own gene therapy for SMA, AVXS-101, no SMA type 1 patients had died so far.

The analyst maintains a Buy rating on AveXis, while raising the price target from $85 to $100.

Pair Trade

“We also open a pair trade of AVXS (long) and IONS (short), on the increasing potential for 1) AVXS-101 use in SMA types 2 and 3, likely at Spinraza's expense, and 2) Spinraza to increase the size of the SMA market ahead of an AVXS-101 launch,” Amusa stated.

The analyst now believes that there is an increasing likelihood that AVXS-101 would eventually be approved for SMA types 2 and 3 as well.

Future Opportunity

AveXis’ end-of-Phase 1 meeting is expected to be held in Q2:17 or Q3:17, after the company announces the 13.6 months of data on all patients from its Phase 1 study in Q1:17.

“We believe that if the results are positive, and safety concerns persist for Spinraza, that AveXis could more easily make a case for earlier AVXS-101 approval across SMA types 1 to 3,” Amusa mentioned.

The analyst estimated a smaller opportunity for AVXS-101 in SMA types 2 and 3 for now, with greater opportunity likely following a nearer term initial approval for AVXS-1-1 or a longer-term label expansion.

Latest Ratings for AVXS

DateFirmActionFromTo
Apr 2018JefferiesDowngradesBuyHold
Apr 2018Chardan CapitalDowngradesBuyNeutral
Apr 2018UBSDowngradesBuyNeutral

View More Analyst Ratings for AVXS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Reiteration Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (BIIB + AVXS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XECImperial CapitalDowngrades35.0
SSTIImperial CapitalUpgrades49.0
AVDLoop CapitalUpgrades29.0
FCREYDeutsche BankUpgrades0.0
OECUBSUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

BlueBird Bio Wounded After Roth Downgrade

Tiffany Rebounds From Downgrade, CEO Departure